Dr Wenbin Wei PhD

 

Senior Bioinformatician

wei-wenbin-Cropped-110x146

Contact details

School of Cancer Sciences

About

Wenbin Wei is a senior bioinformatician. He has a PhD in Molecular Biology and an MSc in Computing Science. He is currently analyzing large amount of genetic, epigenetic, transcriptomic and proteomic data obtained using microarray, mass spectrometry and next generation sequencing. He is interested in the application of bioinformatics and biostatistics to the omics-driven cancer research and the development of new software tools and databases.

Qualifications

  • MSc in Computing Science 2000
  • PhD in Plant Molecular Biology 1997 
  • MSc in Botany 1984 
  • BSc in Botany 1982

Biography

Wenbin Wei studied for a BSc (1982) and an MSc (1984) in the Department of Biology of Nanjing University. He lectured at Nanjing Normal University between 1985 and 1988. He then worked and studied for a PhD at Leicester University until 1996. After that, he worked at Durham University as a research associate until 1999. He studied for an MSc in Computing Sciences (2000) at the University of Newcastle and then worked as a software engineer for two years initially at Foster Findlay Associates Ltd and then at Nonlinear Dynamics Ltd. He has been a bioinformatician at the University of Birmingham since 2003.

Postgraduate supervision

Wenbin Wei is interested in supervising doctoral research students in the following areas:

  • Application of Bioinformatics and Biostatics to the omics-driven cancer research
  • Development of databases and software tools for cancer research

If you are interesting in studying any of these subject areas please contact Wenbin Wei on the contact details above, or for any general doctoral research enquiries, please email: dr@contacts.bham.ac.uk or call +44 (0)121 414 5005.

For a full list of available Doctoral Research opportunities, please visit our Doctoral Research programme listings.

Research

Research Themes

  • Cancer Cell Biology 
  • Cancer Genetics 
  • Viral Oncology 
  • Tumour Immunology 
  • Structural Biology & Biomarkers 
  • Cancer Prevention, Screening, Diagnosis & Survivorship

Research Activity

Wenbin Wei is interested in collaborative research, especially the application of bioinformatics and biostatistics to the omics-driven cancer research, such as viral oncology, cancer biomarker discovery and evaluation, cancer pathogenesis, cancer genetics and epigenetics, and drug development. He analyzes large amount of genetic, epigenetic, transcriptomic and proteomic data obtained using microarray, mass spectrometry and next generation sequencing. He is also interested in the development of new software tools and databases.

He advises collaborators on experimental design and analysis of new experimental data as well as the mining of existing data in public domain. He does both low level and high level analyses. Low level analyses involve data quality assessment, background subtraction and normalization. High level analyses involve the identification of biomarkers (differentially expressed genes and proteins, hyper- and hypo- methylated genomic regions, point mutations, indels and copy number variation) and the classification of patient samples using supervised and unsupervised analyses, such as logistic regression, hierarchical clustering, principle component analysis, partial least square analysis and neural network. He also does survival analysis and provides advice on gene ontology analysis and promoter analysis.

Publications

Automated Pub Med Search for Dr. Wenbin Wei

Smith, N., R. Tierney, W. Wei, M. Vockerodt, P. G. Murray, C. B. Woodman and M. Rowe (2013). "Induction of Interferon-Stimulated Genes on the IL-4 Response Axis by Epstein-Barr Virus Infected Human B Cells; Relevance to Cellular Transformation." PLoS One 8(5): e64868.

Vockerodt M, Wei W, Nagy E, Prouzova Z, Schrader A, Kube D, Rowe M, Woodman CB, Murray PG (2013). Suppression Of The Lmp2a Target Gene, Egr-1, Protects Hodgkin's Lymphoma Cells From Entry To The Ebv Lytic Cycle. J Pathol. 230:399–409.

Shimwell, N. J., R. T. Bryan, W. Wei, N. D. James, K. K. Cheng, M. P. Zeegers, P. J. Johnson, A. Martin and D. G. Ward (2013). "Combined proteome and transcriptome analyses for the discovery of urinary biomarkers for urothelial carcinoma." Br J Cancer 108(9): 1854-1861. 

Shinawi, T., V. K. Hill, D. Krex, G. Schackert, D. Gentle, M. R. Morris, W. Wei, G. Cruickshank, E. R. Maher and F. Latif (2013). "DNA methylation profiles of long- and short-term glioblastoma survivors." Epigenetics 8(2): 149-56. 

Singhal, R., J. B. Carrigan, W. Wei, P. Taniere, R. K. Hejmadi, C. Forde, C. Ludwig, J. Bunch, R. L. Griffiths, P. J. Johnson, O. Tucker, D. Alderson, U. L. Gunther and D. G. Ward (2013). "MALDI profiles of proteins and lipids for the rapid characterisation of upper GI-tract cancers." J Proteomics 80C: 207-215. 

Kelly, G. L., J. Stylianou, J. Rasaiyaah, W. Wei, W. Thomas, D. Croom-Carter, C. Kohler, R. Spang, C. Woodman, P. Kellam, A. B. Rickinson and A. I. Bell (2013). "Different patterns of Epstein-Barr virus latency in endemic Burkitt lymphoma (BL) lead to distinct variants within the BL-associated gene expression signature." J Virol 87(5): 2882-2894.  PMID:23269792.

Reiman, A., X. Lu, L. Seabra, U. Boora, M. S. Nahorski, W. Wei and E. R. Maher (2013). "Gene expression and protein array studies of folliculin-regulated pathways." Anticancer Res 32(11): 4663-4670. 

Shimwell, N. J., D. G. Ward, Y. Mohri, T. Mohri, L. Pallan, M. Teng, Y. C. Miki, M. Kusunoki, O. Tucker, W. Wei, J. Morse and P. J. Johnson (2012). "Macrophage migration inhibitory factor and DJ-1 in gastric cancer: differences between high-incidence and low-incidence areas." Br J Cancer 107(9): 1595-1601. PMID:22968650.

Hu, C., W. Wei, X. Chen, C. B. Woodman, Y. Yao, J. M. Nicholls, I. Joab, S. K. Sihota, J. Y. Shao, K. D. Derkaoui, A. Amari, S. L. Maloney, A. I. Bell, P. G. Murray, C. W. Dawson, L. S. Young and J. R. Arrand (2012). "A global view of the oncogenic landscape in nasopharyngeal carcinoma: an integrated analysis at the genetic and expression levels." PLoS One 7(7): e41055. 

Leonard, S. M., W. Wei, S. I. Collins, M. Pereira, A. Diyaf, C. Constandinou-Williams, L. S. Young, S. Roberts and C. B. Woodman (2012). "Oncogenic human papillomavirus imposes an instructive pattern of DNA methylation changes which parallel the natural history of cervical HPV infection in young women." Carcinogenesis 33(7): 1286-1293. 

Voss, M., R. Ganesan, L. Ludeman, K. McCarthy, R. Gornall, G. Schaller, W. Wei and S. Sundar (2012). "Should grade3 endometrioid carcinoma be considered a type 2 cancer - a clinical and pathological evaluation." Gynecol Oncol. 2012 Jan;124(1):15-20.

Bryan, R., W. Wei, N. J. Shimwell, S. Collins, S. A. Hussain, L. J. Billingham, P. Murray, N. Deshmukh, N. James, M. Wallace, P. J. Johnson, M. P. Zeegers, K. Cheng, A. Martin and D. G. Ward (2011). "Assessment of High-Throughput High-Resolution MALDI-TOF-MS of Urinary Peptides for the Detection of Muscle-Invasive Bladder Cancer." Proteom Clin Appl 5(9-10):493-503.

Leonard, S., W. Wei, J. Anderton, M. Vockerodt, M. Rowe, P. G. Murray and C. B. Woodman (2011). "Epigenetic and Transcriptional Changes Which Follow Epstein-Barr Virus Infection of Germinal Center B Cells and Their Relevance to the Pathogenesis of Hodgkin's Lymphoma." J Virol 85(18): 9568-9577.

Back to top